K121926

5. 510(k) SUMMARY

SEP 20 2012

DATE: February 17, 2010

OWNER:
McKesson Medical Surgical International
70 Sir John Rogerson's Quay
Dublin 2, Ireland

OFFICIAL CORRESPONDENT:
Anthony L. Giaccio
Manager, Quality Systems and Regulatory Affairs
Telephone: 815-385-0100
Fax: 815-385-0114
Email: Anthony.Giaccio@mckesson.com

DEVICE NAME:

Trade Name: Textured, Blue, Latex Powder Free Examination Gloves, Tested For Use With Chemotherapy Drugs With Protein Labeling Claim (50µg/dm2 Or Less Of Water Soluble Protein)

Common Name: Patient Examination Gloves

Classification: Patient Examination Gloves

Class: Class I

Product Code: LZC

PREDICATE DEVICE(S):

Predicate 510(k)	Device Name	Indication	Clearance Date	Company
K083409	Latex Powder Free Examination Gloves (Blue) Tested For Use With Chemotherapy Drugs	The latex examination glove (Tested for Use with Chemotherapy Drugs) is a disposable device intended for medical and dental purposes that is worn on the examiner's hand to prevent contamination between patient and examiner.	29 Jul 2009	WRP ASIA PACIFIC SDN, BHD

DEVICE DESCRIPTION: Textured, Blue, Latex Powder Free Examination Gloves, Tested For Use With Chemotherapy Drugs With Protein Labeling Claim (50µg/dm² Or Less Of Water Soluble Protein).

STATEMENT OF INTENDED USE:

The examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner.

In addition, these gloves were tested for use with chemotherapy drugs in accordance with ASTM D6978-05 Standard Practice for Assessment of Medical Gloves to Permeation of Chemotherapy Drugs:

Chemotherapy Drug Permeation
(Breakthrough Detection Time in Minutes)

Chemotherapy Drug	Average Breakthrough Detection Time (Min)
Carmustine (BCNU) (3.3 mg/mL)	15.4
Cisplatin (1.0 mg/mL)	No breakthrough up to 240 min
Cyclophosphamide (Cytoxan) (20.0 g/mL)	No breakthrough up to 240 min
Dacarbazine (DTIC) (10.0 mg/mL)	No breakthrough up to 240 min
Doxorubicin Hydrochloride (2.0 mg/mL)	No breakthrough up to 240 min
Etoposide (20.0 mg/mL)	No breakthrough up to 240 min
Fluorouracil (Adrucil) (50.0 mg/mL)	No breakthrough up to 240 min
Methotrexate (25.0 mg/mL)	No breakthrough up to 240 min
Mitomycin C (0.5mg/mL)	No breakthrough up to 240 min
Paclitaxel (Taxol) (6.0mg/mL)	No breakthrough up to 240 min
Thiotepa (10.0 mg/mL)	1.6
Vincristine Sulfate (1.0 mg/mL)	No breakthrough up to 240 min

The maximum testing time is 240 minutes. Please note that the following drugs, Carmustine and Thiotepa, have extremely low permeation time of less than 30 minutes.

TECHNOLOGICAL CHARACTERISTICS:

The Latex Powder Free Examination Glove is substantially equivalent to the predicate device with regard to physical characteristics, design, product features, and intended use. Both gloves are made with latex using similar manufacturing processes. In addition, both gloves have been tested for use with chemotherapy drugs.

ASSESSMENT OF NONCLINICAL DATA:

Characteristic	Standard	Device Performance
Dimension	ASTM Standard D3578-05	Meets
Physical Properties	ASTM Standard D3578-05	Meets
Freedom from Pinholes	21 CFR 800.20; ASTM D5151-06	Meets
Powder Residual	ASTM Standard D6124-06	Meets Results generated values below 2mg of residual powder
Protein Level	ASTM Standard D5712-10	Meets Results generated values below 50 mcg/mg of protein
Biocompatibility	Biological Evaluation of Medical Devices part 1: Evaluation and Testing (ISO 10993-1:2009)	Meets
	Primary Skin Irritation in rabbits (ISO 10993-10:2010)	Gloves are non-irritating
	Dermal Sensitization in the guinea pig (ISO 10993-10:2010)	Gloves do not display any potential for sensitization

CONCLUSIONS:

The Latex Powder Free Examination Gloves meet the requirements of established standards ASTM D3578-05, ASTM D5712-10, ASTM D5151-06, ASTM D6124-06 ISO 10993-1:2009 and ISO 10993-10:2010.

Based on the comparison of intended use, design, materials and performance, the Latex Powder Free Examination Gloves Tested for Use With Chemotherapy Drugs are substantially equivalent to the predicate device.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room –WO66-G609
Silver Spring, MD 20993-0002

SEP 20 2012

Northstar Healthcare Holdings
C/O Mr. Ned Devine
Senior Staff Engineer
Underwriters Laboratories, Incorporated
333 Pfingsten Road
Northbrook, Illinois 60062

Re: K121926
Trade/Device Name: Textured, Blue, Latex Powder Free Examination Gloves, Tested For Use With Chemotherapy Drugs With Protein Labeling Claim (50 $\mu g/dm^2$ Or Less Of Water Soluble Protein)
Regulation Number: 21 CFR 880.6250
Regulation Name: Patient Examination Gloves
Regulatory Class: Class I
Product Code: LZC
Dated: September 4, 2012
Received: September 5, 2012

Dear Mr. Devine:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

For

Anthony D. Watson, B.S., M.S., M.B.A.
Director
Division of Anesthesiology, General Hospital,
Infection Control and Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

INDICATIONS FOR USE

510(k) Number (if known): K121926

Device Name: **Textured, Blue, Latex Powder Free Examination Gloves, Tested For Use With Chemotherapy Drugs With Protein Labeling Claim (50µg/dm² Or Less Of Water Soluble Protein).**

Indications for Use: The examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner.

In addition, these gloves were tested for use with chemotherapy drugs in accordance with ASTM D6978-05 Standard Practice for Assessment of Medical Gloves to Permeation of Chemotherapy Drugs:

Chemotherapy Drug and Concentration	Minimum Breakthrough Detection Time in Minutes
Carmustine (BCNU)(3.3 mg/mL)	15.4
Cisplatin (1.0 mg/mL)	>240
Cyclophosphamide (Cytoxan) (20.0 mg/mL)	>240
Dacarbazine (DTIC) (10.0 mg/mL)	>240
Doxorubicin Hydrochloride (2.0 mg/mL)	>240
Etoposide (20.0 mg/mL)	>240
Fluorouracil (Adrucil) (50.0 mg/mL)	>240
Methotrexate (25 mg/mL)	>240
Mitomycin C (0.5mg/mL)	>240
Paclitaxel (taxol) (6.0 mg/mL)	>240
Thiotepa (10.0 mg/mL)	1.6
Vincristine Sulfate (1.0 mg/mL)	>240

The maximum testing time is 240 minutes. Please note that the following drugs, Carmustine (BCNU) and Thiotepa have extremely low permeation time of less than 30 minutes.

AND/OR

Prescription Use_____
(Part 21 CFR 801 Subpart D)

Over-The-Counter Use ___X___
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of Anesthesiology, General Hospital Infection Control, Dental Devices

510(k) Number: K121926